NICOLA HANANIA to Bronchodilator Agents
This is a "connection" page, showing publications NICOLA HANANIA has written about Bronchodilator Agents.
Connection Strength
13.118
-
POINT: Should Triple Inhaled Therapy Be Considered in All Patients With Group E COPD? Yes. Chest. 2024 Jul; 166(1):12-17.
Score: 0.780
-
Revisiting Mild Asthma: Current Knowledge and Future Needs. Chest. 2022 01; 161(1):26-39.
Score: 0.643
-
Management of asthma COPD overlap. Ann Allergy Asthma Immunol. 2019 10; 123(4):335-344.
Score: 0.555
-
Long-term safety and efficacy of formoterol fumarate inhalation solution in patients with moderate-to-severe COPD. Int J Chron Obstruct Pulmon Dis. 2019; 14:117-127.
Score: 0.533
-
COPD Management in the Primary Care Setting. J Fam Pract. 2018 10; 67(10 Suppl):S27-S32.
Score: 0.524
-
Long-term health-related quality-of-life and symptom response profiles with arformoterol in COPD: results from a 52-week trial. Int J Chron Obstruct Pulmon Dis. 2018; 13:499-508.
Score: 0.501
-
Emerging inhaled long-acting beta-2 adrenoceptor agonists for the treatment of COPD. Expert Opin Emerg Drugs. 2017 09; 22(3):285-299.
Score: 0.486
-
Ten years of tiotropium: clinical impact and patient perspectives. Int J Chron Obstruct Pulmon Dis. 2013; 8:117-25.
Score: 0.357
-
New bronchodilators. Curr Opin Pharmacol. 2012 Jun; 12(3):238-45.
Score: 0.333
-
Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respir Med. 2012 Jan; 106(1):91-101.
Score: 0.324
-
Bronchodilator reversibility in COPD. Chest. 2011 Oct; 140(4):1055-1063.
Score: 0.322
-
Safety of chronic obstructive pulmonary disease medications: a primary care perspective. Postgrad Med. 2011 May; 123(3):72-9.
Score: 0.313
-
Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial. Respir Res. 2011 Jan 11; 12:6.
Score: 0.307
-
Budesonide/formoterol combination in COPD: a US perspective. Int J Chron Obstruct Pulmon Dis. 2010 Oct 05; 5:357-66.
Score: 0.301
-
The safety and efficacy of arformoterol and formoterol in COPD. COPD. 2010 Feb; 7(1):17-31.
Score: 0.287
-
Clinical implications of the intrinsic efficacy of beta-adrenoceptor drugs in asthma: full, partial and inverse agonism. Curr Opin Pulm Med. 2010 Jan; 16(1):1-5.
Score: 0.286
-
Efficacy and safety of nebulized formoterol as add-on therapy in COPD patients receiving maintenance tiotropium bromide: Results from a 6-week, randomized, placebo-controlled, clinical trial. Drugs. 2009 Jun 18; 69(9):1205-16.
Score: 0.275
-
Asthma in older adults. Clin Chest Med. 2007 Dec; 28(4):685-702, v.
Score: 0.247
-
Pharmacologic interventions in chronic obstructive pulmonary disease: bronchodilators. Proc Am Thorac Soc. 2007 Oct 01; 4(7):526-34.
Score: 0.244
-
Optimizing maintenance therapy for chronic obstructive pulmonary disease: strategies for improving patient-centered outcomes. Clin Ther. 2007 Oct; 29(10):2121-33.
Score: 0.244
-
Update on the pharmacologic therapy for chronic obstructive pulmonary disease. Clin Chest Med. 2007 Sep; 28(3):589-607, vi-vii.
Score: 0.243
-
The role of intrinsic efficacy in determining response to a beta2-agonist in acute severe asthma. Respir Med. 2007 May; 101(5):1007-14.
Score: 0.229
-
Acute asthma in pregnancy. Crit Care Med. 2005 Oct; 33(10 Suppl):S319-24.
Score: 0.213
-
Comparative effectiveness of inhaled fluticasone propionate/salmeterol and budesonide/formoterol fixed-dose combinations in asthma control - a retrospective United States database analysis. Respir Med. 2025 Aug-Sep; 245:108172.
Score: 0.208
-
The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD. Pulm Pharmacol Ther. 2005; 18(1):19-22.
Score: 0.202
-
Impact of antiviral therapy on short- and long-term outcomes of patients with chronic obstructive pulmonary disease after influenza infection. Influenza Other Respir Viruses. 2023 12; 17(12):e13231.
Score: 0.188
-
Influence of baseline bronchodilator reversibility and blood eosinophils on lung function in patients with asthma following omalizumab. J Allergy Clin Immunol Pract. 2024 02; 12(2):512-514.e2.
Score: 0.188
-
Adding tiotropium or long-acting ?2-agonists to inhaled corticosteroids: Asthma-related exacerbation risk and healthcare resource utilization. Allergy Asthma Proc. 2023 11 13; 44(6):413-421.
Score: 0.187
-
COPD Exacerbations, Costs, and Health Care Resource Utilization Before and After Initiation of Fluticasone Furoate/Umeclidinium/Vilanterol in Routine Care in the USA. Int J Chron Obstruct Pulmon Dis. 2023; 18:407-418.
Score: 0.179
-
Reducing the Risk of Mortality in Chronic Obstructive Pulmonary Disease With Pharmacotherapy: A Narrative Review. Mayo Clin Proc. 2023 02; 98(2):301-315.
Score: 0.177
-
Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis. Respir Med. 2022 12; 205:107040.
Score: 0.174
-
Efficacy of dupilumab in patients with moderate-to-severe asthma and persistent airflow obstruction. Ann Allergy Asthma Immunol. 2023 02; 130(2):206-214.e2.
Score: 0.174
-
Pharmacologic Management Strategies of Asthma-Chronic Obstructive Pulmonary Disease Overlap. Immunol Allergy Clin North Am. 2022 08; 42(3):657-669.
Score: 0.171
-
Effect of Age on Efficacy and Safety of Fluticasone Furoate/Vilanterol (FF/VI), Umeclidinium (UMEC), and UMEC + FF/VI in Patients with Chronic Obstructive Pulmonary Disease: Analyses of Five Randomized Clinical Trials. Int J Chron Obstruct Pulmon Dis. 2021; 16:1925-1938.
Score: 0.158
-
Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies. Int J Chron Obstruct Pulmon Dis. 2021; 16:865-875.
Score: 0.156
-
Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial. Chest. 2021 03; 159(3):985-995.
Score: 0.151
-
Activity-related dyspnea in chronic obstructive pulmonary disease: physical and psychological consequences, unmet needs, and future directions. Int J Chron Obstruct Pulmon Dis. 2019; 14:1127-1138.
Score: 0.137
-
Impact of doxofylline compared to theophylline in asthma: A pooled analysis of functional and clinical outcomes from two multicentre, double-blind, randomized studies (DOROTHEO 1 and DOROTHEO 2). Pulm Pharmacol Ther. 2018 Dec; 53:20-26.
Score: 0.131
-
New developments in optimizing bronchodilator treatment of COPD: a focus on glycopyrrolate/formoterol combination formulated by co-suspension delivery technology. Int J Chron Obstruct Pulmon Dis. 2018; 13:2805-2819.
Score: 0.130
-
Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension? Delivery Technology in patients with chronic obstructive pulmonary disease. Respir Med. 2017 05; 126:105-115.
Score: 0.118
-
Hospital management of acute exacerbations of chronic obstructive pulmonary disease. J Hosp Med. 2015 May; 10(5):328-39.
Score: 0.103
-
The asthma COPD overlap syndrome (ACOS). Curr Allergy Asthma Rep. 2015 Mar; 15(3):509.
Score: 0.102
-
One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD. Chest. 2014 Dec; 146(6):1531-1542.
Score: 0.100
-
Evaluating the safety of COPD medications: an evidence-based review. Chest. 2013 Oct; 144(4):1357-1367.
Score: 0.093
-
Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD. Respir Med. 2014 Feb; 108(2):366-75.
Score: 0.093
-
The effects of cigarette smoke on airway inflammation in asthma and COPD: therapeutic implications. Respir Med. 2012 Mar; 106(3):319-28.
Score: 0.082
-
A unified front against COPD: clinical practice guidelines from the American College of Physicians, the American College of Chest Physicians, the American Thoracic Society, and the European Respiratory Society. Chest. 2011 Sep; 140(3):565-566.
Score: 0.080
-
Clinical and economic burden of depression/anxiety in chronic obstructive pulmonary disease patients within a managed care population. COPD. 2011 Aug; 8(4):293-9.
Score: 0.080
-
Nebulized formoterol provides added benefits to tiotropium treatment in chronic obstructive pulmonary disease. Adv Ther. 2009 Nov; 26(11):1024-34.
Score: 0.071
-
Long-term safety of nebulized formoterol: results of a twelve-month open-label clinical trial. Ther Adv Respir Dis. 2008 Aug; 2(4):199-208.
Score: 0.065
-
It's about time--directing our attention toward modifying the course of COPD. Respir Med. 2008 Jun; 102 Suppl 1:S37-48.
Score: 0.064
-
Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance. Ther Adv Respir Dis. 2008 Apr; 2(2):37-48.
Score: 0.063
-
Effect of nebulized arformoterol on airway function in COPD: results from two randomized trials. COPD. 2008 Feb; 5(1):25-34.
Score: 0.063
-
Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: a 2-week, multicenter, randomized, open-label study. Clin Ther. 2008; 30 Spec No:989-1002.
Score: 0.062
-
Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial. Clin Ther. 2007 Feb; 29(2):261-78.
Score: 0.058
-
A comparison of levalbuterol with racemic albuterol in the treatment of acute severe asthma exacerbations in adults. Am J Emerg Med. 2006 May; 24(3):259-67.
Score: 0.055
-
Treatments for COPD. Respir Med. 2005 Dec; 99 Suppl B:S28-40.
Score: 0.053
-
The challenge of differentiating asthma from chronic obstructive pulmonary disease. Manag Care. 2005 Jul; 14(7 Suppl Obstructie Lung):9-15; discussion 24-6.
Score: 0.052
-
The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study. Clin Ther. 2005 May; 27(5):531-42.
Score: 0.052
-
Cardiovascular Events with the Use of Long-Acting Muscarinic Receptor Antagonists: An Analysis of the FAERS Database 2020-2023. Lung. 2024 04; 202(2):119-125.
Score: 0.047
-
Clinic vs?Home Spirometry for Monitoring Lung Function in Patients With Asthma. Chest. 2023 11; 164(5):1087-1096.
Score: 0.045
-
Dupilumab Efficacy in Steroid-Dependent Severe Asthma by Baseline Oral Corticosteroid Dose. J Allergy Clin Immunol Pract. 2022 07; 10(7):1835-1843.
Score: 0.042
-
Results of a Patient Survey Regarding COPD Knowledge, Treatment Experiences, and Practices With Inhalation Devices. Respir Care. 2018 07; 63(7):833-839.
Score: 0.032
-
Factors Determining In Vitro Lung Deposition of Albuterol Aerosol Delivered by Ventolin Metered-Dose Inhaler. J Aerosol Med Pulm Drug Deliv. 2017 Aug; 30(4):256-266.
Score: 0.029
-
Characteristics and outcomes of older adults with long-standing versus late-onset asthma. J Asthma. 2017 04; 54(3):223-229.
Score: 0.028
-
A simple rule to identify patients with chronic obstructive pulmonary disease who may need treatment reevaluation. Respir Med. 2014 Sep; 108(9):1310-20.
Score: 0.024
-
Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013 May; 1(3):210-23.
Score: 0.022
-
Perceptions and attitudes toward the use of nebulized therapy for COPD: patient and caregiver perspectives. COPD. 2013 Aug; 10(4):482-92.
Score: 0.022
-
Examining fatigue in COPD: development, validity and reliability of a modified version of FACIT-F scale. Health Qual Life Outcomes. 2012 Aug 23; 10:100.
Score: 0.021
-
Lebrikizumab treatment in adults with asthma. N Engl J Med. 2011 Sep 22; 365(12):1088-98.
Score: 0.020
-
Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med. 2011 Aug 02; 155(3):179-91.
Score: 0.020